Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses.
Anderson Matheus Pereira da Silva, Daniel Vicente de Siqueira Lima, Rachid Figueiroa Souza et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of cannabinoid-based therapies for agitation in Alzheimer's disease, involving 221 participants across seven studies. Results indicated that cannabinoid therapies significantly reduced neuropsychiatric symptoms and agitation scores compared to placebo, with a standardized mean difference of -0.31 for the NPI total score. However, cognitive benefits were not consistently observed.
Key findings
- Cannabinoid therapies reduced NPI total scores with a standardized mean difference of -0.31.
- CMAI-SF scores showed a significant reduction with a standardized mean difference of -0.40.
- NPI agitation/aggression scores decreased with a standardized mean difference of -0.47.
- Somnolence was identified as the main safety concern with a risk ratio of 2.25.
Why it matters
Agitation in Alzheimer's disease significantly impacts patient care and caregiver burden. Understanding the potential role of cannabinoid therapies could inform treatment strategies and improve quality of life for patients and caregivers.
What to keep in mind
Interpretation is limited by the small number of trials, heterogeneous formulations, and short follow-up periods.